Wilson developed a novel de-coppering agent as a new treatment for Wilson disease. This is a rare genetic disorder that prevents the body from regulating copper levels and can lead to serious liver and brain damage. The product works by removing the abnormal accumulation of copper from the liver, brain and other organs. Existing treatments are inadequate and frequently have debilitating side-effects. Wilson went public in May 2016 and was acquired by Alexion for $855 million in May 2018.